skip to main content
Idioma:

A scoping review of the use of cannabidiol in psychiatric disorders

Kirkland, Anna E. ; Fadus, Matthew C. ; Gruber, Staci A. ; Gray, Kevin M. ; Wilens, Timothy E. ; Squeglia, Lindsay M.

Psychiatry research, 2022-02, Vol.308, p.114347-114347, Article 114347 [Periódico revisado por pares]

Ireland: Elsevier B.V

Texto completo disponível

Citações Citado por
  • Título:
    A scoping review of the use of cannabidiol in psychiatric disorders
  • Autor: Kirkland, Anna E. ; Fadus, Matthew C. ; Gruber, Staci A. ; Gray, Kevin M. ; Wilens, Timothy E. ; Squeglia, Lindsay M.
  • Assuntos: Anxiety ; Anxiety - drug therapy ; Anxiety Disorders - drug therapy ; Autism Spectrum Disorder - drug therapy ; Cannabidiol - pharmacology ; Cannabidiol - therapeutic use ; CBD ; Clinicians ; Humans ; Mental Disorders - drug therapy ; Psychiatry ; Psychosis ; Treatment
  • É parte de: Psychiatry research, 2022-02, Vol.308, p.114347-114347, Article 114347
  • Descrição: •Cannabidiol (CBD) is a phytocannabinoid in the cannabis sativa plant that has gained widespread attention for its potential role in psychiatry research.•Mental health clinicians are now challenged to rapidly adapt to the growing body of literature regarding the use of CBD in psychiatric disorders.•Upon review for the literature, the most promising preliminary findings are related to the use of CBD in psychotic symptoms and anxiety.•There is currently not enough high-quality evidence to suggest the clinical use of CBD for any psychiatric disorder.•Summary tables of the current clinical evidence and frequently asked questions are included as a guide for mental health practitioners. Cannabidiol (CBD) has become a fast-growing avenue for research in psychiatry, and clinicians are challenged with understanding the implications of CBD for treating mental health disorders. The goal of this review is to serve as a guide for mental health professionals by providing an overview of CBD and a synthesis the current evidence within major psychiatric disorders. PubMed and PsycINFO were searched for articles containing the terms “cannabidiol” in addition to major psychiatric disorders and symptoms, yielding 2952 articles. Only randomized controlled trials or within-subject studies investigating CBD as a treatment option for psychiatric disorders (N = 16) were included in the review. Studies were reviewed for psychotic disorders (n = 6), anxiety disorders (n = 3), substance use disorders (tobacco n = 3, cannabis n = 2, opioid n = 1), and insomnia (n = 1). There were no published studies that met inclusion criteria for alcohol or stimulant use disorder, PTSD, ADHD, autism spectrum disorder, or mood disorders. Synthesis of the CBD literature indicates it is generally safe and well tolerated. The most promising preliminary findings are related to the use of CBD in psychotic symptoms and anxiety. There is currently not enough high-quality evidence to suggest the clinical use of CBD for any psychiatric disorder.
  • Editor: Ireland: Elsevier B.V
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.